Amicus Therapeutics (FOLD) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Oil market losses easing as nearly 80% of disrupted supply returns, UBS says
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates
August 5, 2015 4:01 PM EDTMarketing Submissions for Galafold® (migalastat HCl) for Fabry Disease Under Review in Europe and on Track for Filing in 2H15 in United States
2Q15 Equity Financing Significantly Strengthens Balance Sheet; More Than $350M Cash on Hand
International Commercial Leadership Team Nearly Complete
Phase 1/2 Clinical Study Initiation of Next-Generation Pompe ERT in 2H15
CRANBURY, N.J., Aug. 5, 2015 (GLOBE NEWSWIRE) --... More
